GRDN
Guardian Pharmacy Services, Inc.
GRDN's fundamentals are strong: free cash flow grew 47% and earnings per share grew 83%. At 42x earnings, it's trading below its usual 48x. Analysts expect that strong growth to continue.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GRDN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
GRDN's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GRDN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 34x | $49.38 | — |
| Current | 42x | $49.38 | — |
| Cheap | 44x | $51.74 | +4.8% |
| Fair | 48x | $56.09 | +14% |
| Expensive | 51x | $59.75 | +21% |
Historical ranges are pointers, not guarantees.
GRDN's PE is in its cheap range at 42x. If earnings grow as analysts expect, today's price would be 34x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GRDN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
GRDN has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
GRDN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.47 | +25% |
| Q3 2026 | $1.17 | +83% |
| Q2 2026 | $1.03 | +$2.54 |
| Q1 2026 | $0.83 | +$2.31 |
| Q4 2025 | $0.77 | +$2.54 |
| Q3 2025 | $0.64 | +$2.23 |
| Q2 2025 | -$1.51 | -786% |
| Q1 2025 | -$1.48 | -470% |
| Q4 2024 | -$1.77 | -411% |
GRDN has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
GRDN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $371.1M | -1.7% |
| Q2 2026 | $351.8M | +2.2% |
| Q1 2026 | $336.6M | +2.2% |
| Q4 2025 | $397.6M | +17% |
| Q3 2025 | $377.4M | +20% |
| Q2 2025 | $344.3M | +15% |
| Q1 2025 | $329.3M | +20% |
| Q4 2024 | $338.6M | +20% |
GRDN's revenue is growing: $371M last quarter, down 1.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.8% | +2.3 points |
| Q2 2026 | 5.9% | +2.2 points |
| Q1 2026 | 5.3% | +1.3 points |
| Q4 2025 | 9.2% | +4.2 points |
| Q3 2025 | 4.5% | +38 points |
| Q2 2025 | 3.6% | -2 points |
| Q1 2025 | 4% | +1.1 points |
| Q4 2024 | 5% | -0.6 points |
GRDN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over GRDN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
GRDN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $43.4M | +89% |
| Q2 2026 | $25.4M | +63% |
| Q1 2026 | $1M | -91% |
| Q4 2025 | $30.4M | +70% |
| Q3 2025 | $23M | +$30.3M |
| Q2 2025 | $15.6M | -40% |
| Q1 2025 | $11.7M | +137% |
| Q4 2024 | $17.8M | +51% |
GRDN generated $100M in free cash flow over the past year, up 47% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over GRDN on cash flow, with more consistent year-over-year improvement.
GRDN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +80K shares |
| 1 year | +0.8% | +484K shares |
| 3 years | +5% | +3.1M shares |
| 5 years | +5% | +3.1M shares |
| Available history | +5% | +3.1M shares |
GRDN has 64M diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | $30.3M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $29M |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GRDN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GRDN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | -0.5x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.3x | Net Cash |
| Q3 2025 | -0.0x | Net Cash |
| Q2 2024 | 1.4x | Healthy |
| Q1 2024 | -0.0x | Net Cash |
| Q4 2023 | 1.2x | Healthy |
GRDN has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
GRDN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 67.4 | Neutral |
| Stochastic | 60.9 | Neutral |
GRDN's weekly RSI is 67 (neutral) and its Stochastic is 61 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GRDN PE vs Healthcare Sector
| Metric | GRDN | Sector median | Relative |
|---|---|---|---|
| PE | 42x | 26x | 63% above |
| PE % | 8 | 59 | 51 pts below |
GRDN is trading at 42x earnings, a 63% premium to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GRDN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $42.0 | 17% above |
| 20 week MA | $41.3 | 20% above |
| 50 week MA | $37.5 | 32% above |
| 100 week MA | $30.3 | 63% above |
GRDN has stronger trend alignment. GRDN is above 4 of 4 weekly averages versus HIMS above 0 of 5.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GRDN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $17.8 | $21.2 | +19% |
| 2025 | $21.2 | $30.7 | +45% |
| 2026 YTD | $30.7 | $49.4 | +61% |
GRDN has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.